{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Tumor+Marker+Analysis&page=2", "query": { "intervention": "Laboratory Tumor Marker Analysis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1897, "total_pages": 190, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Tumor+Marker+Analysis&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Laboratory+Tumor+Marker+Analysis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T14:39:04.712Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00946712", "title": "S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Large Cell Lung Carcinoma", "Recurrent Lung Adenocarcinoma", "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Large Cell Lung Carcinoma", "Stage IV Lung Adenocarcinoma", "Stage IV Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1333, "start_date": "2009-07-15", "completion_date": "2022-02-08", "has_results": true, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 797, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946712" }, { "nct_id": "NCT00754494", "title": "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenomatous Polyp", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage I Colon Cancer", "Stage I Rectal Cancer", "Stage IIA Colon Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2008-07", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 3, "location_summary": "Long Beach, California • Orange, California • Chicago, Illinois", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754494" }, { "nct_id": "NCT02584829", "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Merkel Cell Polyomavirus Infection", "Stage IV Merkel Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Interferon Beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-11-06", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584829" }, { "nct_id": "NCT00381641", "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Thyroid Gland Oncocytic Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2006-08-29", "completion_date": "2024-12-10", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 17, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381641" }, { "nct_id": "NCT03070002", "title": "Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Carcinoma Metastatic in the Bone", "Circulating Tumor Cell Count", "Estrogen Receptor Positive", "HER2/Neu Negative", "Progesterone Receptor Positive", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Denosumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2017-10-19", "completion_date": "2018-04-24", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 2, "location_summary": "Chicago, Illinois • Lake Forest, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070002" }, { "nct_id": "NCT00030693", "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "recombinant fowlpox-B7.1 vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030693" }, { "nct_id": "NCT01038778", "title": "Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Kidney Carcinoma", "Stage III Renal Cell Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2009-10-29", "completion_date": "2027-02-12", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Buffalo, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01038778" }, { "nct_id": "NCT00671034", "title": "Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia", "Childhood B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Calaspargase Pegol-mknl", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 166, "start_date": "2008-07-21", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2021-04-27", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671034" }, { "nct_id": "NCT00303849", "title": "Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Mixed Glioma", "Oligoastrocytoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mannitol", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sodium Thiosulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2005-09-15", "completion_date": "2021-03-12", "has_results": false, "last_update_posted_date": "2022-03-17", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Portland, Oregon", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303849" }, { "nct_id": "NCT00569543", "title": "Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2005-05-11", "completion_date": "2012-08-02", "has_results": false, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-09-30T14:39:04.712Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Omaha, Nebraska", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569543" } ] }